" class="no-js "lang="en-US"> XNK Therapeutics - Medtech Alert
Friday, April 12, 2024

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
XNK Therapeutics | Pharmtech Focus

XNK Therapeutics

About XNK Therapeutics

XNK Therapeutics

Realizing the potential in autologous NK cell therapies for cancer patients

Related Story

Appointments

 XNK Therapeutics Appoints Hugo Petit as Chief Financial Officer | MTA

XNK Therapeutics Appoints Hugo Petit as Chief Financial Officer

June 7 2023

XNK Therapeutics today announced the appointment of Hugo Petit as Chief Financial Officer (CFO) and […]

Diseases

 XNK Receives EU Tissue Establishment Certificate | MTA

XNK Receives EU Tissue Establishment Certificate

April 3 2023

XNK Therapeutics today announced that it has been approved as an EU Tissue Establishment. This […]

Diseases

 XNK Therapeutics Raises SEK 132 Million to Accelerate Growth | Pharmtech Focus

XNK Therapeutics Raises SEK 132 Million to Accelerate Growth

March 29 2022

XNK Therapeutics AB (“XNK”) today announced it has secured a private placement of SEK 132 million, […]

Appointments

 XNK Therapeutics Appoints Markus Thor as Chief Business Officer | Pharmtech Focus

XNK Therapeutics Appoints Markus Thor as Chief Business Officer

September 3 2021

XNK Therapeutics AB today announced the appointment of Markus Thor as Chief Business Officer, effective September 6th. He […]